Celcuity Inc
CELCHealthcare|Biotechnology|USA
$107.58
-5.93 (-5.22%)
Tangible Book
$1.11
Earnings Power
$1.12
Upcoming Data Readouts (3)
Jan 2028
Est. completion
P1P2mCRPC (Metastatic Castration-resistant Prostate Cancer)
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
NCT06190899n=54
Aug 2028
Est. completion
P2Endometrial Cancer
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer
NCT03675893n=110
Mar 2029
Est. completion
P3Breast Cancer
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634n=1,180
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Jun 2026
P3
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886Jul 2024
P1P2
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
NCT03911973